A Multicenter, Randomized Controlled Study of the Efficacy of Once-Weekly DPP-4 Inhibitor Omarigliptin in Patients with Type 2 Diabetes Undergoing Maintenance Hemodialysis

被引:0
|
作者
Yoshizawa, Yuta
Hosojima, Michihiro
Kabasawa, Hideyuki
Tanabe, Naohito
Kitamura, Tadahiro
Narita, Ichiei
Saito, Akihiko
机构
关键词
D O I
10.2337/db19-29-LB
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
29-LB
引用
收藏
页数:2
相关论文
共 50 条
  • [41] A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval
    Tatosian, Daniel A.
    Marricco, Nadia Cardillo
    Glasgow, Xiaoli Shirley
    DeGroot, Bruce
    Dunnington, Katherine
    George, Laura
    Gendrano, Isaias Noel
    Johnson-Levonas, Amy O.
    Swearingen, Dennis
    Kauh, Eunkyung
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2016, 5 (05): : 383 - 392
  • [42] Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
    Kamrul-Hasan, A. B. M.
    Alam, Muhammad Shah
    Talukder, Samir Kumar
    Dutta, Deep
    Selim, Shahjada
    ENDOCRINOLOGY AND METABOLISM, 2024, 39 (01) : 109 - 126
  • [43] Single-/Multiple- Dose Pharmacokinetics (PK) and Pharmacodynamics (PD) of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, in Healthy Subjects
    Krishna, Rajesh
    Addy, Carol
    Tatosian, Daniel
    Hou, Xiaoli S.
    Gendrano, Isaias N.
    Martucci, Ashley N.
    Wagner, John A.
    Stoch, S. Aubrey
    DIABETES, 2013, 62 : A284 - A284
  • [44] Effectiveness of DPP-4 Inhibitors on Blood Glucose Variability in Type 2 Diabetes Patients Undergoing Hemodialysis
    Ishikawa, Tomomi
    Hosojima, Michihiro
    Kabasawa, Hideyuki
    Kaseda, Ryohei
    Kuwahara, Shoji
    Iino, Noriaki
    Tanaka, Takahiro
    Kitamura, Nobutaka
    Suzuki, Yoshiki
    Narita, Ichiei
    Saito, Akihiko
    DIABETES, 2017, 66 : LB29 - LB29
  • [45] Evolution of a Manufacturing Route to Omarigliptin, A Long-Acting DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
    Chung, John Y. L.
    Scott, Jeremy P.
    Anderson, Camille
    Bishop, Brian
    Bremeyer, Nadine
    Cao, Yang
    Chen, Qmghao
    Dunn, Robert
    Kassim, Amude
    Lieberman, David
    Moment, Aaron J.
    Sheen, Faye
    Zacuto, Michael
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2015, 19 (11) : 1760 - 1768
  • [46] Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of Multiple-Dose Administration of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, in Obese Subjects With and Without Type 2 Diabetes Mellitus (T2DM)
    Addy, Carol
    Tatosian, Daniel
    Hou, Xiaoli S.
    Gendrano, Isaias N.
    Martucci, Ashley
    Groff, Michelle
    Wagner, John A.
    Stoch, S. Aubrey
    DIABETES, 2013, 62 : A287 - A287
  • [47] Does the Glucose-Lowering Action of Omarigliptin, a Weekly DPP-4 Inhibitor, Last over a Week in Japanese Type 2 Diabetic Patients?
    Taniguchi, Yukiko
    Onishi, Tetsuro
    Mori, Yutaka
    DIABETES, 2017, 66 : A325 - A325
  • [48] Once-Weekly Dulaglutide with Insulin Therapy for Type 2 Diabetes: Efficacy and Safety Results from a Phase 4, Randomized, Placebo-Controlled Study
    Hitoshi Ishii
    Yukiko Onishi
    Tomonori Oura
    Masakazu Takeuchi
    Diabetes Therapy, 2020, 11 : 133 - 145
  • [49] Once-Weekly Dulaglutide with Insulin Therapy for Type 2 Diabetes: Efficacy and Safety Results from a Phase 4, Randomized, Placebo-Controlled Study
    Ishii, Hitoshi
    Onishi, Yukiko
    Oura, Tomonori
    Takeuchi, Masakazu
    DIABETES THERAPY, 2020, 11 (01) : 133 - 145
  • [50] The Clinical Efficacy and Treatment Satisfaction of Weekly DPP-4 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus
    Tosaki, Takahiro
    Kamiya, Hideki
    Himeno, Tatsuhito
    Kato, Yoshiro
    Kondo, Masaki
    Inagaki, Akemi
    Yamamoto, Yuka
    Mizubayashi, Ryuichi
    Tsubonaka, Kaori
    Oshiro, Chie
    Nakaya, Yuki
    Nakamura, Jiro
    DIABETES, 2016, 65 : A300 - A300